Assessing Post-Marketing Requirements for Orphan Drugs: A Cross-Sectional Analysis of FDA and EMA Oversight : Clinical Pharmacology and Therapeutics
| dc.contributor.author | Jae Hyeon Yu1,† , Sangwon Lee 2,3,† , Yoon Jung Kim 1, Won Young Kim 1, Min Jung Lee 1 and Yun Kim 1, * | |
| dc.date.accessioned | 2024-09-03T05:23:14Z | |
| dc.date.available | 2024-09-03T05:23:14Z | |
| dc.date.issued | 2024-09-03 | |
| dc.identifier.uri | http://98.70.32.231:4000/handle/123456789/1339 | |
| dc.publisher | Wiley | |
| dc.title | Assessing Post-Marketing Requirements for Orphan Drugs: A Cross-Sectional Analysis of FDA and EMA Oversight : Clinical Pharmacology and Therapeutics | |
| dc.type | Article |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Clin Pharma and Therapeutics - 2024 - Yu - Assessing Post‐Marketing Requirements for Orphan Drugs A Cross‐Sectional.pdf
- Size:
- 1.44 MB
- Format:
- Adobe Portable Document Format
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed to upon submission
- Description: